The economics of bladder cancer: Costs and considerations of caring for this disease

European Urology

Volumn 66, Issue 2, 2014, Pages 253-262

  Svatek, Robert S ^a   Hollenbeck, Brent K ^b   Holmäng, Sten ^c   Lee, Richard ^d   Kim, Simon P ^e   Stenzl, Arnulf ^f   Lotan, Yair ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Klinik für Urologie   (Germany)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Charge; Cost; Cost effectiveness

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; CISPLATIN; DOXORUBICIN; METHOTREXATE; VALRUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; CYSTOSCOPY; DISEASE SEVERITY; FOLLOW UP; HEALTH CARE COST; HUMAN; LENGTH OF STAY; LYMPH NODE DISSECTION; MAINTENANCE THERAPY; MEDICAL SUBJECT HEADINGS; META ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW; TERMINAL CARE; TRANSURETHRAL RESECTION; CARCINOMA, TRANSITIONAL CELL; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; ECONOMICS; FEE; HEALTH SURVEY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROLOGIC EXAMINATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; COST SAVINGS; COST-BENEFIT ANALYSIS; CYSTECTOMY; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, UROLOGICAL; FEES AND CHARGES; HEALTH CARE COSTS; HUMANS; PERIOPERATIVE CARE; POPULATION SURVEILLANCE; RADIOTHERAPY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84904068134     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.01.006     Document Type: Review

References (88)

1. A.B. Mariotto, K.R. Yabroff, Y. Shao, E.J. Feuer, and M.L. Brown Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 2011 117 128
2. E.B.C. Avritscher, C.D. Cooksley, and H.B. Grossman et al. Clinical model of lifetime cost of treating bladder cancer and associated complications Urology 68 2006 549 553
3. G.F. Riley, A.L. Potosky, J.D. Lubitz, and L.G. Kessler Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis Med Care 33 1995 828 841
4. S.A. Strope, Z. Ye, J.M. Hollingsworth, and B.K. Hollenbeck Patterns of care for early stage bladder cancer Cancer 116 2010 2604 2611
5. T.A. Skolarus, Z. Ye, S. Zhang, and B.K. Hollenbeck Regional differences in early stage bladder cancer care and outcomes Urology 76 2010 391 396
6. B.K. Hollenbeck, Z. Ye, R.L. Dunn, J.E. Montie, and J.D. Birkmeyer Provider treatment intensity and outcomes for patients with early-stage bladder cancer J Natl Cancer Inst 101 2009 571 580
7. J.M. Hollingsworth, Y. Zhang, S.L. Krein, Z. Ye, and B.K. Hollenbeck Understanding the variation in treatment intensity among patients with early stage bladder cancer Cancer 116 2010 3587 3594
8. S.A. Strope, S.H. Chang, L. Chen, G. Sandhu, J.F. Piccirillo, and M. Schootman Survival impact of followup care after radical cystectomy for bladder cancer J Urol 190 2013 1698 1703
9. K.R. Yabroff, W.W. Davis, and E.B. Lamont et al. Patient time costs associated with cancer care J Natl Cancer Inst 99 2007 14 23
10. K.R. Yabroff, C.J. Bradley, A.B. Mariotto, M.L. Brown, and E.J. Feuer Estimates and projections of value of life lost from cancer deaths in the United States J Natl Cancer Inst 100 2008 1755 1762
11. M.F. Botteman, C.L. Pashos, A. Redaelli, B. Laskin, and R. Hauser The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
12. H. Hedelin, S. Holmäng, and L. Wiman The cost of bladder tumour treatment and follow-up Scand J Urol Nephrol 36 2002 344 347
13. R.S. Svatek, D. Lee, and Y. Lotan Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard? Urology 66 2005 65 68
14. I.A. Sternberg, G.E. Paz, and L.Y. Chen et al. Upper tract imaging surveillance is not effective in diagnosing upper tract recurrences in patients followed for non-muscle-invasive bladder cancer J Urol 190 2013 1187 1191
15. K.D. Sievert, B. Amend, and U. Nagele et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295 300
16. D.A. Green, M. Rink, and E.K. Cha et al. Cost-effective treatment of low-risk carcinoma not invading bladder muscle BJU Int 111 2013 E78 E84
17. H. Mostafid, and M. Brausi Measuring and improving the quality of transurethral resection for bladder tumour (TURBT) BJU Int 109 2012 1579 1582
18. P. Mariappan, S.M. Finney, and E. Head et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking BJU Int 109 2012 1666 1673
19. S. Kruck, J. Bedke, and J. Hennenlotter et al. Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics Urol Int 87 2011 138 142
20. M. Babjuk, W. Oosterlinck, and R. Sylvester et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
21. H.W. Herr Role of re-resection in non-muscle-invasive bladder cancer ScientificWorldJournal 11 2011 283 288
22. S. Holmäng High-grade non-muscle-invasive bladder cancer: is re-resection necessary in all patients before intravesical bacillus Calmette-Guerin treatment? Scand J Urol 47 2013 363 369
23. K. Davenport, F.X. Keeley Jr., and A.G. Timoney Audit of safety, efficacy, and cost-effectiveness of local anaesthetic cystodiathermy Ann Royal Coll Surg Engl 92 2010 706 709
24. H.W. Herr, S.M. Donat, and V.E. Reuter Management of low grade papillary bladder tumors J Urol 178 2007 1201 1205 discussion 1205
25. D.S. Park, J.H. Hwang, I.H. Gong, D.K. Choi, M.H. Kang, and J.J. Oh An analysis of the efficacy, safety, and cost-effectiveness of fulguration under local anesthesia for small-sized recurrent masses: a comparative analysis to transurethral resection of bladder tumors in a matched cohort J Endourol 2013 271240 271244
26. S.M. Donat, A. North, G. Dalbagni, and H.W. Herr Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm J Urol 171 2004 636 639
27. O.N. Gofrit, D. Pode, A. Lazar, R. Katz, and A. Shapiro Watchful waiting policy in recurrent Ta G1 bladder tumors Eur Urol 49 2006 303 307 discussion 306-7
28. M.A. Brausi, G. Verrini, and G. De Luca et al. The use of local anesthesia with N-DO injector (Physion) for transurethral resection (TUR) of bladder tumors and bladder mapping: preliminary results and cost-effectiveness analysis Eur Urol 52 2007 1407 1413
29. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
30. M. Babjuk, M. Burger, and R. Zigeuner et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
31. P.E. Clark, N. Agarwal, and M.C. Biagioli et al. Bladder cancer J Natl Compr Canc Netw 11 2013 446 475
32. M.C. Hall, S.S. Chang, and G. Dalbagni et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314 2330
33. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190 quiz 2435
34. I. Berrum-Svennung, T. Granfors, S. Jahnson, H. Boman, and S. Holmäng A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101 105 discussion 105-6
35. K. Chamie, C.S. Saigal, and J. Lai et al. Quality of care in patients with bladder cancer: a case report? Cancer 118 2012 1412 1421
36. R. Madeb, D. Golijanin, and K. Noyes et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors Cancer 115 2009 2660 2670
37. C.T. Lee, D. Barocas, and D.R. Globe et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases J Urol 188 2012 2114 2119
38. R.J. Sylvester, M.A. van der, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
39. A. Uchida, H. Yonou, and E. Hayashi et al. Intravesical instillation of bacille Calmette-Guerin for superficial bladder cancer: cost-effectiveness analysis Urology 69 2007 275 279
40. J. Oddens, M. Brausi, and R. Sylvester et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
41. T. O'Brien Is fluorescent cystoscopy of cost/benefit/therapeutic value for carcinoma in situ of the bladder? No (a difficult task) J Urol 190 2013 20 21
42. T. Karaolides, A. Skolarikos, and A. Bourdoumis et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80 2012 354 359
43. M. Burger, H.B. Grossman, and M. Droller et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 64 2013 846 854
44. H.B. Grossman, A. Stenzl, and Y. Fradet et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
45. P. Shen, J. Yang, and W. Wei et al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis BJU Int 110 2012 E209 E215
46. M. Burger, D. Zaak, and C.G. Stief et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis Eur Urol 52 2007 142 147
47. Y. Lotan Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con J Urol 187 2012 1538 1539
48. Y. Lotan, S.F. Shariat, and B.J. Schmitz-Drager et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Urol Oncol 28 2010 441 448
49. A.M. Kamat, P.K. Hegarty, and J.R. Gee et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers Eur Urol 63 2013 4 15
50. E. Xylinas, L.A. Kluth, M. Rieken, P.I. Karakiewicz, Y. Lotan, and S.F. Shariat Urine markers for detection and surveillance of bladder cancer Urol Oncol 32 2014 222 229
51. Y. Lotan, and C.G. Roehrborn Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach J Urol 167 2002 75 79
52. J.J. Crivelli, E. Xylinas, L.A. Kluth, M. Rieken, M. Rink, and S.F. Shariat Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature Eur Urol 65 2014 742 754
53. A. Wyszynski, S.A. Tanyos, and J.R. Rees et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer Cancer 120 2014 408 414
54. D. Schrag, N. Mitra, and F. Xu et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population Urology 65 2005 1118 1125
55. P.J. Gray, S.A. Fedewa, and W.U. Shipley et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base Eur Urol 63 2013 823 829
56. J.G. Augoustides, M.D. Neuman, L. Al-Ghofaily, and G. Silvay Preoperative cardiac risk assessment for noncardiac surgery: defining costs and risks J Cardiothorac Vasc Anesth 27 2013 395 399
57. H.R.H. Patel, Y. Cerantola, and M. Valerio et al. Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy? Eur Urol. 65 2014 263 266
58. Y. Cerantola, M. Valerio, and B. Persson et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®) society recommendations Clin Nutr 32 2013 879 887
59. A. Karl, A. Buchner, and A. Becker et al. A new concept for early recovery after surgery in patients undergoing radical cystectomy for bladder cancer - results of a prospective randomized study J Urol. 191 2014 335 340
60. S.P. Kim, N.D. Shah, and R.J. Karnes et al. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer J Urol 187 2012 2011 2017
61. B.J. Davies, V. Allareddy, and B.R. Konety Effect of postcystectomy infectious complications on cost, length of stay, and mortality Urology 73 2009 598 602
62. I. Berrum-Svennung, H. Hedelin, and S. Holmäng Costs of radical cystectomy Scand J Urol Nephrol 39 2005 36 41
63. A. Shabsigh, R. Korets, and K.C. Vora et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology Eur Urol 55 2009 164 176
64. R.S. Svatek, M.B. Fisher, and S.F. Matin et al. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria J Urol 183 2010 929 934
65. T. Asgeirsson, K.I. El-Badawi, A. Mahmood, J. Barletta, M. Luchtefeld, and A.J. Senagore Postoperative ileus: it costs more than you expect J Am Coll Surg 210 2010 228 231
66. J.A. Ramirez, A.G. McIntosh, R. Strehlow, V.A. Lawrence, D.J. Parekh, and R.S. Svatek Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review Eur Urol 64 2013 588 597
67. J.F. Foss, D.M. Fisher, and V.D. Schmith Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials Clin Pharmacol Ther 83 2008 770 776
68. W.M. Hilton, Y. Lotan, D.J. Parekh, J.W. Basler, and R.S. Svatek Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis BJU Int 111 2013 1054 1060
69. C.O. Mmeje, A.D. Martin, R. Nunez-Nateras, A.S. Parker, D.D. Thiel, and E.P. Castle Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy Curr Urol Rep 14 2013 26 31
70. Z.L. Smith, J.P. Christodouleas, S.M. Keefe, S.B. Malkowicz, and T.J. Guzzo Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy BJU Int 112 2013 13 25
71. R.C. Chen, W.U. Shipley, J.A. Efstathiou, and A.L. Zietman Trimodality bladder preservation therapy for muscle-invasive bladder cancer J Natl Compr Canc Netw 11 2013 952 960
72. G. Mowatt, S. Zhu, and M. Kilonzo et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer Health Technol Assess 14 2010 1 331 iii-iv
73. H. von der Maase, S.W. Hansen, and J.T. Roberts et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
74. P. Robinson, H. Maase, and S. Bhalla et al. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Expert Rev Pharmacoecon Outcomes Res 4 2004 27 38
75. E. Winquist, T.S. Kirchner, R. Segal, J. Chin, and H. Lukka Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561 569
76. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
77. Neoadjuvant chemotherapy for invasive bladder cancer Cochrane Database Syst Rev 2005 CD005246
78. U. Fedeli, S.A. Fedewa, and E.M. Ward Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007 J Urol 185 2011 72 78
79. G. Ercolani, A. Cucchetti, and M. Cescon et al. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases Eur J Cancer 47 2011 2291 2298
80. A. Parthan, M.R. Posner, C. Brammer, P. Beltran, and J.P. Jansen Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck Head Neck 31 2009 1255 1262
81. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 206 discussion 205-6
82. J. Sleeper, and Y. Lotan Economics of bladder cancer diagnosis and surveillance V. Lokeshwar, Bladder tumors: molecular aspects and clinical management 2011 Humana Press New York, NY 121 137
83. Y. Lotan, R.S. Svatek, and A.I. Sagalowsky Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis Cancer 107 2006 982 990
84. G. Iyer, H. Al-Ahmadie, and N. Schultz et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer J Clin Oncol 31 2013 3133 3140
85. J.S. Ross, K. Wang, and R.N. Al-Rohil et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy Mod Pathol 27 2014 271 280
86. P.U. Malmstrom, H. Hedelin, Y.K. Thomas, G.J. Thompson, H. Durrant, and J. Furniss Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden Scand J Urol Nephrol 43 2009 192 198
87. M. Racioppi, A. Volpe, and R. Falabella et al. The cost of treatment and follow-up of bladder cancer in Italy Arch Ital Urol Androl 79 2007 111 117
88. A. Stenzl, J. Hennenlotter, and D. Schilling Can we still afford bladder cancer? Curr Opin Urol 18 2008 488 492